TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
CVS Pharmacy and subsidiaries agreed to pay $315 million to resolve a Justice Department lawsuit alleging they unlawfully filled opioid prescriptions without a legitimate medical purpose. CVS said it disputes the allegations, and the settlement does not admit wrongdoing; it also requires additional safeguards for dispensing controlled substances.
CVS Pharmacy and several subsidiaries have agreed to pay $315 million to resolve a U.S. Justice Department lawsuit alleging the company unlawfully dispensed medically unnecessary opioid prescriptions. The agreement also requires additional safeguards for opioid and other controlled-substance dispensing; CVS disputes the allegations and says the settlement admits no wrongdoing.
The settlement resolves a lawsuit filed in 2024 under the Controlled Substances Act. The Justice Department alleged CVS filled prescriptions for high doses of potent opioids that lacked a legitimate medical purpose and contributed to dependence and addiction. It also alleged that some prescriptions came from providers it described as “pill mills”, which it said issued drugs without a legitimate medical purpose.
In its complaint, the department said CVS dispensed large quantities of opioids and other controlled substances, with many prescriptions billed to and reimbursed by Medicaid and other federal health programs. Prosecutors further alleged that staffing levels, performance measures and incentive compensation policies encouraged pharmacists to fill prescriptions quickly without adequately confirming their legitimacy. These are allegations in the lawsuit; the settlement does not establish them as findings of wrongdoing by CVS.
Beyond the payment, the agreement requires CVS to implement additional safeguards so controlled substances are dispensed only when medically appropriate, according to Assistant Attorney General Brett Shumate. The source report does not specify the payment schedule, how the funds will be distributed, or the precise operational details and oversight arrangements for the new safeguards.
New Controls on CVS Dispensing
The agreement combines a substantial financial resolution with changes to how CVS handles opioid and other controlled-substance prescriptions. The new safeguards may affect pharmacy procedures for reviewing prescriptions, although the available announcement does not detail how those procedures will work or how compliance will be measured.
The case also reflects federal efforts to hold companies accountable for their role in the opioid crisis. The Justice Department framed the settlement as a step in enforcement against pharmacies that it alleges unlawfully filled prescriptions. For patients and pharmacy staff, the practical effects will depend on the safeguards CVS adopts and how they are applied while maintaining access to appropriate treatment.
pharmacy prescription review scanner
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
The 2024 Case and Wider Settlements
The Justice Department filed the CVS lawsuit in 2024, during President Joe Biden’s administration. The complaint alleged that CVS violated the Controlled Substances Act by filling illegitimate prescriptions, including prescriptions for high doses of potent opioids. CVS said at the time that pharmacists faced “vague, undefined, and ever-changing standards” for deciding whether to fill opioid prescriptions.
The CVS agreement follows years of opioid-related settlements involving drugmakers, wholesalers, pharmacies and other companies. The source report says those settlements with U.S. governments total more than $50 billion over the past decade, with most agreements and funds involving state and local governments. It also points to federal deals with Walgreens and Walmart in the previous two years. Settlement totals and arrangements vary, and the report does not provide a breakdown of the CVS payment’s eventual recipients.
““Today’s settlement is a significant milestone in the Justice Department’s efforts to combat the opioid epidemic by cracking down on pharmacies who unlawfully fulfill prescriptions for controlled substances.””
— Associate Attorney General Stanley Woodward
controlled substance medication lock box
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Settlement Terms Still Undisclosed
The source report does not state when or how the $315 million will be paid, which governments or programs will receive the money, or whether any part will be allocated to specific opioid-response efforts. It also gives no timetable for implementing the added safeguards or details on audits, reporting, or penalties for noncompliance.
The underlying allegations remain disputed: the Justice Department described conduct it said violated federal law, while CVS denied the claims and the settlement admits no wrongdoing. The available information does not say whether the agreement includes other terms beyond the payment and safeguards, or whether any related claims remain pending.
As an affiliate, we earn on qualifying purchases.
Implementation and Case Closure
CVS is expected to carry out the additional dispensing safeguards required by the agreement. The reported announcement does not identify a public implementation schedule, a compliance monitor, or the next court or agency milestone. Further information about those terms would clarify how the changes will be enforced and tracked.
The settlement resolves the 2024 Justice Department lawsuit, according to the report. The next developments to watch are the release of detailed settlement documents, the timing and distribution of the payment, and information about how CVS’s revised procedures will operate in pharmacies.
As an affiliate, we earn on qualifying purchases.
Key Questions
How much will CVS pay?
CVS Pharmacy and subsidiaries agreed to pay $315 million to resolve the Justice Department case. The report does not provide a payment schedule or distribution breakdown.
What did the Justice Department allege?
The department alleged that CVS unlawfully filled opioid and other controlled-substance prescriptions that lacked a legitimate medical purpose, including prescriptions it said came from “pill mills.” It also alleged that company practices contributed to pharmacists filling prescriptions without adequate review. These claims were disputed and were not established by the settlement.
Did CVS admit wrongdoing?
No. CVS said it strongly disagrees with the lawsuit’s allegations and that the settlement admits no wrongdoing.
What changes does the settlement require?
CVS must implement additional safeguards so prescriptions for opioids and other controlled substances are dispensed only when medically appropriate. The announcement did not detail the safeguards or explain how compliance will be monitored.
Where will the settlement money go?
The available report does not specify how the $315 million will be distributed. It also does not say whether the funds are earmarked for particular opioid prevention, treatment or recovery programs.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
